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ABSTRACT  17 
This study aimed to evaluate the performance of the Unyvero P50 pneumonia assay, the first 18 
‘sample-in, answer-out’ system for rapid identification of pathogens and antibiotic resistance 19 
markers directly from clinical specimens. Overall, Unyvero P50 displayed very good sensitivity 20 
(>95%); however, specificity was low (33%) mainly due to the fact that 40% of the specimens 21 
were reported as normal flora. Specifically, one or more pathogens were identified in 28 of 22 
them. From a detailed analysis of 42 specimens selected at random, 76% of the additionally 23 
reported pathogens were confirmed present in primary specimens. Detection of selected 24 
resistance markers was compared to routine phenotypic susceptibility testing, supplemented 25 
with Checkpoints microarray system, PCR and sequencing. Concordance was mixed, primarily 26 
due to issues with panel’s choice of markers and detection of some intrinsic beta-lactamases. 27 
Finally, we offer a critical analysis of the assay’s microbial panel and resistance markers and 28 
provide suggestions for improvement.  29 
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INTRODUCTION 32 
Pneumonia is defined as consolidative infection of the lower respiratory tract causing 33 
significant morbidity and mortality worldwide. In the UK, (infectious and non-infectious) 34 
respiratory diseases accounts for 20% of deaths [1] and in 2006, the British Thoracic Society 35 
reported that pneumonia alone accounted for over 1/3 of these [1]. Pneumonia can be 36 
categorised as community-acquired (CAP) if acquired outside of the healthcare setting, or as 37 
hospital-acquired (HAP), when the onset of disease/clinical presentation occurs >48h after 38 
hospital admission [2]. In the clinical setting, of particular concern are patients undergoing 39 
intensive or critical care, who develop HAP or ventilator-associated pneumonia (VAP), often as 40 
a consequence of aspiration and prolonged hospital stay, or related to mechanical ventilation 41 
[3]. This prolonged stay along with the use of empirical broad-spectrum antibiotics may result 42 
in infection with multi-drug resistant organisms often associated with high mortality [4]. 43 
Pneumonia can be caused by a wide variety of bacteria, viruses or fungi that cannot easily be 44 
distinguished by clinical presentation [5]. Current routine diagnostic methods are mainly 45 
culture-based, which are limited by low sensitivity and unsuitability for detecting atypical 46 
pathogens. At present, turnaround times for routine culture and antimicrobial susceptibility 47 
testing range from 48-72h; in the meantime, the patient receives empirical antimicrobial 48 
therapy [6]. Such empirical therapy may be compromised by antimicrobial resistance or be used 49 
unnecessarily to treat infections caused by viruses or susceptible bacteria, thus driving the 50 
development of antimicrobial resistance [7,8]. Hence, a rapid test for detecting microorganisms 51 
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and their associated susceptibility profiles to direct therapy in pneumonia is urgently needed; 52 
both for better prognosis of patients [9] and improved antimicrobial stewardship [10].  53 
Although there has been an emergence of real-time PCR assays targeted towards respiratory 54 
diagnosis, a single method available for rapidly identifying the variety of pathogenic causes of 55 
pneumonia is lacking. Accordingly, we evaluated the Curetis Unyvero P50 Pneumonia assay, the 56 
first ‘sample-in and answer-out’ system capable of diagnosing pneumonia aetiology directly 57 
from clinical specimens. This test combines automated sample preparation with multiplex PCR 58 
for selected targets and microarray hybridisation for amplicon detection. It promises to detect 59 
16 bacteria and one fungus as well as 18 antibiotic resistance markers in around five hours 60 
(Table 1). 61 
  62 
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MATERIALS AND METHODS 63 
Specimen Collection and Analysis 64 
We collected anonymised respiratory specimens surplus to clinical requirements from adult in-65 
patients with suspected pneumonia at two tertiary care hospitals in London: the Royal Free 66 
(RFH) and University College London Hospitals (UCLH), from December 2014 to June 2015. 67 
Duplicate specimens from the same patient were excluded unless collected >6 days apart. Fresh 68 
specimens from patients with radiological confirmation of pneumonia were stored at 4°C until 69 
processing (within 48h). Curetis Unyvero P50 Pneumonia assay was run as per manufacturer’s 70 
instructions with a turnaround time of approximately 5h (30 min for mechanical and chemical 71 
sample lysis and homogenisation followed by 4h30 for DNA purification, multiplex PCR and 72 
microarray detection). Detailed information of the system and method can be found on the 73 
manufacturer’s website (www.curetis.com).  74 
 75 
Routine Clinical Microbiology 76 
Results were compared to those released by the routine clinical microbiology laboratories of 77 
the two participating hospitals. For the RFH, this comprised 1:1 v/v dilution with dithiothreitol, 78 
semi-quantitative cultures onto three agar plates (Columbia Blood Agar (CBA), Colombia agar 79 
with chocolated horse blood (CHOC) and cystine lactose electrolyte deficient agar (CLED)); 80 
identification MALDI-TOF MS (Bruker Microflex™ LT) and antimicrobial susceptibility testing 81 
(AST) with the BD Phoenix system or by disc diffusion following EUCAST guidelines [11]. For 82 
UCLH, undiluted specimens were cultured onto CBA, CHOC and CLED, organisms were identified 83 
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using MALDI-TOF or the BioMerieux VITEK2 system and AST was performed using the VITEK 2 or 84 
BSAC (British Society for Antimicrobial Chemotherapy) standardised disc susceptibility testing. 85 
Atypical species Chlamydophila pneumoniae, Legionella pneumophila and Mycoplasma 86 
pneumoniae are screened using an in house qPCR assay at RFH and by antigen testing or 87 
serology at UCLH. MycAssay® Pneumocystis (Myconostica) is used to detect Pneumocystis 88 
jirovecii at RFH, at UCLH it is detected by Grocott-Gomori's methenamine silver stain. 89 
 90 
Comprehensive Microbiological Analysis 91 
For a full comprehensive analysis, 42 specimens were chosen at random. A cross-sectional 92 
sweep of growth was taken from a fresh primary culture of the specimen on CHOC and stored 93 
in MicrobankTM vials at -80°C until analysis. Ten µL of neat and a 10-5 dilution in saline solution 94 
were plated onto CHOC, CBA, Brilliance UTI agar (UTI) and Columbia colistin-nalidixic acid agar 95 
(C-CNA) (Oxoid). CBA, UTI and C-CNA plates were incubated at 37°C in air for 18h while CHOC 96 
plates were incubated in 5% CO2 at 37°C for 18h. Representative bacterial colonies of different 97 
morphologies on each medium were identified using MALDI-TOF MS. 98 
For bacterial isolates identified during the comprehensive microbiological analysis, 99 
susceptibility to beta-lactam antibiotics was evaluated using the disk diffusion method on 100 
Mueller-Hinton agar following EUCAST recommendations [11]. The following antibacterial 101 
agents (Oxoid) were tested: Aztreonam (30µg), Piperacillin-tazobactam (10-6µg), Ceftazidime 102 
(10µg), Imipenem (10µg), Meropenem (10µg), Temocillin (30µg) for Enterobacteriaceae, 103 
Acinetobacter spp. and Pseudomonas spp.; Ertapenem (10µg), Ampicillin (10 µg), Amoxiclav (20-104 
10µg), Cefoxitin (30µg), Cefotaxime (5µg) were also tested for Enterobacteriaceae. Cefoxitin 105 
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(30µg) discs were used for identification of potential methicillin resistant Staphylococcus aureus 106 
(MRSA). Ciprofloxacin susceptibility testing was performed on P. aeruginosa and Escherichia coli 107 
using the gradient diffusion method (Etest®, Biomérieux), interpreted according to EUCAST 108 
guidelines (http://www.eucast.org/clinical breakpoints/). Both laboratories report predominant 109 
growth of potentially pathogenic species equivalent to 105 CFU/ml or above.  110 
Double disc diffusion for detection of beta-lactamases was performed using ROSCO Diagnostica 111 
kits. KPC/Metallo-beta-lactamase and OXA-48 Confirm Kit; KPC/MBL in P. 112 
aeruginosa/Acinetobacter and Total ESBL+AmpC Confirm kits were used according to 113 
manufacturer’s instructions. 114 
  115 
Sequence-based Detection of Resistance Mechanisms 116 
We extracted DNA from resistant bacteria using QIAmp DNA Mini Kit (Qiagen) following 117 
manufacturer’s instructions. The Check-MDR CT103XL test (Checkpoints, NL) was used for 118 
molecular detection and identification of genes encoding carbapenemase, AmpC and ESBL 119 
enzymes according to manufacturer’s instructions. All suspected ESBL, AmpC and 120 
carbapenemase positives were confirmed by PCR (HotStart Taq Mastermix, Qiagen). The 121 
presence of mecA among suspected MRSA and the quinolone resistance-determining regions 122 
(QRDR) of the gyrA and parC genes from fluoroquinolone resistant E. coli or P. aeruginosa were 123 
amplified by PCR. All PCR amplicons were sent for DNA sequencing using the Sanger method at 124 
Beckman Coulter Genomics and analysed using BioNumerics (Applied Maths) software and 125 
NCBI’s BLAST. All primers used in this study are listed in Table S1. 126 
 127 
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Data analysis 128 
The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and 129 
positive and negative likelihood ratios were calculated using MedCalc for Windows. Overall 130 
sensitivity and specificity were calculated considering a test result as true positive when both 131 
routine culture reported an organism and Unyvero P50 identified the same organism, 132 
regardless of additional organisms that may have been identified by Unyvero P50. False 133 
positives were specimens where one or more organisms detected by Unyvero P50 were not 134 
found by routine microbiology. False negatives were specimens where routine microbiology 135 
detected an organism that the Unyvero P50 missed and true negatives were specimens where 136 
neither method reported significant organisms. 137 
During analysis of resistance determinants, only genes considered potentially significant (Table 138 
1) were included; mecA was only considered significant when detected simultaneously with S. 139 
aureus, in such cases presence of MRSA was presumed. During comprehensive culture analysis, 140 
detections of S. mitis group bacteria other than S. pneumoniae were ignored.  141 
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RESULTS 142 
A total of 103 respiratory clinical specimens from hospital in-patients with pneumonia were 143 
tested using the CE-marked Unyvero P50 Pneumonia assay (Unyvero P50) and results were 144 
compared to those generated by the clinical microbiology laboratories.  145 
Unyvero P50 targets (Table 1) are distributed across eight independent PCR chambers. 146 
Complete test failure occurred for 6 specimens while partial test failures (where one or more of 147 
the chambers failed) occurred in 7 specimens. These specimens were excluded leaving a total of 148 
90 specimens for analysis from 84 patients; comprising 55 sputa, 32 endotracheal tubes (ETT) 149 
aspirates and 3 bronchoalveolar lavage (BAL). Radiologic and clinical confirmation of 150 
pneumonia was sought and the type of pneumonia was classified into HAP, VAP or CAP using 151 
standard definitions [2]. The vast majority of our specimens came from patients with HAP 152 
(n=49), while 21 and 20 specimens were from VAP and CAP patients respectively. 153 
On average Unyvero P50 identified a greater number of potential pathogens than routine 154 
microbiology per specimen (1.59 vs 0.59). The most common organisms reported by the culture 155 
laboratories were P. aeruginosa (n=13), S. maltophilia (n=6) and S. marcescens (n=6) whereas 156 
the most common organisms detected by Unyvero P50 were S. maltophilia (n=27), P. 157 
aeruginosa (n=19) and the S. mitis group (n=13) (Table 2, Table S2).  158 
 159 
The number of organisms detected per specimen varied, with routine clinical laboratory 160 
reporting more than one organism in only 5 specimens, whereas Unyvero P50 detected 161 
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polymicrobial flora in 44 specimens (48.9%) (Figure 1). Normal respiratory flora (NRF), non-162 
significant growth (NSG) or mixed growth of doubtful significance (MGODS) was reported for 39 163 
specimens (43%), whereas 3 specimens (3.3%) produced no growth. Unyvero P50, which is not 164 
a quantitative test, identified at least one organism in 74 specimens (82.2%) and was negative 165 
for 16 specimens (17.8%) including the 3 that produced no growth. Complete results for all 166 
specimens are shown in Table S2. 167 
Results from Unyvero P50 and standard microbiology culture were concordant in 59 specimens 168 
(65.5%) (Figure 2). Of these, negative results were concordant in 14 specimens, Unyvero P50 169 
identified only the same pathogen(s) as routine culture in 23 specimens, and the same 170 
pathogen and at least one additional species in 22 specimens. Non-concordant results occurred 171 
in the remaining 31 specimens, which included 28 specimens reported as NRF, NSG or MGODS. 172 
On the other hand, two specimens described negative by Unyvero P50 were found to contain a 173 
pathogen by the clinical laboratory: one specimen contained H. influenzae while the other was 174 
positive for E. faecalis, an organism not associated with pneumonia and not a target of Unyvero 175 
P50. A third specimen was reported by the laboratory as containing H. influenzae, whereas 176 
Unyvero P50 detected K. pneumoniae, P. aeruginosa and S. maltophilia.  177 
Overall clinical diagnostic accuracy metrics for Unyvero P50 indicates a sensitivity of 95.7% 178 
while specificity was 32.6% mainly due to the fact that over 40% of samples were reported as 179 
normal flora whereas Unyvero P50 reported an organism in the majority of samples. Positive 180 
predictive value was 60.8% while negative predictive value was 87.5%. 181 
 182 
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Detection of antimicrobial resistance 183 
The clinical laboratories reported a total of 53 organisms (Table S3), 36% of these were fully 184 
susceptible, 60% resistant to one or more antimicrobial classes and 39.6% multi-drug resistant 185 
(MDR) [12]. Unyvero P50, capable of detecting 18 antibiotic resistance markers, reported 71% 186 
of specimens with at least one resistance marker (including 6 from specimens where no 187 
organism was detected). Many of these markers (e.g. blaTEM, ermB and sul1) are highly 188 
prevalent, if not ubiquitous, among both pathogenic and commensal bacterial populations [13], 189 
hence their detection in mixed specimens, such as those from the respiratory tract, becomes 190 
extremely common.  191 
For this reason, we restricted our analysis to ESBLs, AmpC beta-lactamases, carbapenemases, 192 
presumptive MRSA, and fluoroquinolone resistance (FQR) among E. coli and P. aeruginosa only. 193 
Unyvero P50 identified 17 occurrences of these resistance markers whilst routine microbiology 194 
identified corresponding resistance phenotypes in 14 isolates. In 4 specimens where significant 195 
pathogens were detected by routine microbiology and a target of Unyvero P50 was confirmed 196 
present by independent molecular analysis, the test had identified the resistance marker 197 
correctly in 3 cases (Table 3). An additional 9 clinical bacterial isolates had phenotypic AmpC or 198 
carbapenem resistance not detected by Unyvero P50. In 6 cases the additional molecular 199 
analysis did not identify a cause for resistance (presumably due to overexpression of 200 
chromosomal AmpC enzymes or mutation of porins [14,15]) while A. baumannii producing 201 
OXA-23 carbapenemase was detected in 3 specimens. 202 
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Conversely Unyvero P50 identified several resistance markers, which were not detected by 203 
routine microbiology (Table 3). Two putative MRSA that had been missed by routine methods 204 
were detected (one sample was reported as NRF, the other was reported as containing A. 205 
baumannii). Unyvero P50 also identified a blaCTX-M in a specimen containing K. pneumoniae and 206 
S. maltophilia, whereas routine microbiology reported the specimen as NRF. For AmpCs, 207 
Unyvero P50 identified 3 blaEBC and 2 blaDHA genes. In 4 of the specimens, the clinical laboratory 208 
reported NRF and in the final specimen the clinical laboratory identified an E. cloacae isolate. 209 
For carbapenemases, Unyvero P50 identified 5 specimens with blaOXA-51, all containing A. 210 
baumannii whereas routine microbiology reported NRF for two of the specimens and OXA-23 211 
producing A. baumannii for the remaining three. For fluoroquinolone resistance, routine 212 
microbiology and Unyvero P50 both identified 2 E. coli with gyrA mutations resulting in 213 
ciprofloxacin resistance. For P. aeruginosa one FQR isolate with confirmed mutations in gyrA 214 
was however missed by Unyvero P50, whereas Unyvero P50 identified one P. aeruginosa with 215 
gyrA and parC mutations in a specimen reported as NRF.   216 
Resolution of discrepant results 217 
Culture of respiratory specimens is considered the ‘gold standard’ to identify the microbial 218 
aetiology of pneumonia caused by fungi and bacteria. Limitations of this method include the 219 
cut-off loads (typically 105 CFU/ml) and the subjective interpretation of results, which may vary 220 
among and between laboratories and individual staff members. For this reason, we performed 221 
a more comprehensive analysis for 42 specimens selected at random by identifying all 222 
organisms included on the Unyvero P50 panel that grew on the primary chocolate agar plate. 223 
Our comprehensive investigative culturing method detected one organism in 27 specimens and 224 
 
13 
 
2 organisms in 13 specimens, the remaining two specimens had 4 and 0 organisms respectively. 225 
In comparison, the routine laboratory reported one organism for only 23 of them, and two 226 
organisms for 1 specimen. The main species under-reported by the clinical laboratory were S. 227 
maltophilia (3 vs 12), P. aeruginosa (7 vs 15) and K. pneumoniae (0 vs 4).  228 
Of the 42 specimens analysed, results were concordant with Unyvero P50 in 36 specimens 229 
(85.7%) including an exact match for 25 specimens while Unyvero P50 detected extra 230 
organism(s) in 11 specimens. Conversely comprehensive culture revealed the presence of 231 
additional organisms for 4 specimens: K. oxytoca, S. maltophilia, S. marcescens and E. cloacae 232 
were not detected in one specimen each. Two specimens were found to contain polymicrobial 233 
flora with both methods but some of the reported organisms were discordant (Table S4).  234 
All isolated organisms were screened for relevant resistance phenotypes in order to verify 235 
concordance and control for the possibility of resistant organisms missed by both methods. It 236 
was unfortunately only possible to verify a portion of the discrepant resistance results. 237 
Comprehensive culture confirmed the presence of a CTX-M producing K. pneumoniae, a DHA 238 
producing M. morganii, and a FQR P. aeruginosa in specimens where routine microbiology 239 
reported only NRF. One detection of blaDHA was not verified by comprehensive analysis of the 240 
same specimen. Additionally, comprehensive culture detected an EBC producing E. cloacae and 241 
an MRSA, which had been missed by both routine microbiology and Unyvero P50. Two 242 
detections of EBC and two detections of MRSA, allegedly missed by the routine laboratory, 243 
could not be verified because these specimens were not included in the random selection 244 
(Table S5).   245 
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DISCUSSION 246 
Accurate microbiological diagnosis of lower respiratory tract infections (LRTIs) is notoriously 247 
difficult with as many as 70% of patients never receiving a microbiological diagnosis [16]. Deep 248 
lung specimens such as BAL have less contamination from the upper respiratory microflora and 249 
are therefore preferable for diagnosis, but due to economic and practical issues, sputa and ETT 250 
aspirates are most common in the UK. This study was conducted in order to evaluate the 251 
performance of the Curetis Unyvero P50 diagnostic test, the first “sample-in, answer-out” test 252 
available on the market for rapid diagnosis of LRTIs. The preceding prototype system was 253 
evaluated in a multi-centre study [17] and the full commercial system has been evaluated in 254 
Kuwait [18] and Germany [19]. However, this constitutes the first performance evaluation for 255 
this test in the UK, and more importantly, is the first study to include a detailed analysis of 256 
antimicrobial resistance detection and the first to use an additional method to resolve 257 
discrepancies between routine culture and Unyvero P50. 258 
The Unyvero P50 test successfully detected almost all organisms reported as significant by 259 
routine microbiology from 90 surplus specimens of patients with confirmed severe LRTI (overall 260 
sensitivity=95.7%). The exceptions were 2 organisms (E. faecalis and C. koserii) not included on 261 
the detection panel and 2 instances of H. influenzae. Conversely, the headline specificity of the 262 
test for pathogen detection was poor, with many specimens described as normal flora (NRF, 263 
NSG, MGODS) by routine microbiology.  264 
Test or system failures occurred for 12.6% of specimens, which is of concern. Approximately 265 
half of these were partial failures, whereby the test failed because of errors in one or more 266 
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reaction chambers. In such cases a result is still available but will exclude targets from the failed 267 
chamber(s). Currently, the system does not list these unreliable targets to the user who cannot 268 
therefore judge whether or not to make use of the valid results.  269 
A more in-depth culture-based analysis method was used for 42 randomly selected specimens 270 
to gain a better understanding of the reasons for discrepant results. This analysis revealed that, 271 
in this selection, 76% of cases where Unyvero P50 had reported additional organisms, these 272 
were genuinely present and viable in primary specimens. This still leaves a number of 273 
detections that cannot be explained this way. There are several possible reasons for this; such 274 
as presence of nucleic acid from non-viable organisms, uneven distribution of bacteria within 275 
the specimens or technical issues with the specificity and sensitivity of detection (i.e. errors 276 
relating to the sensitivity and specificity of the PCR assays or microarray detection). We found 277 
the comprehensive culture method a good way of further probing the specimens and would 278 
recommend its use in other similar evaluations.  279 
Analysis of the resistance results was more complex. Many of the resistance markers included 280 
on the Unyvero P50 panel are common among commensals of the respiratory tract. We 281 
therefore restricted our analysis to markers where resistance could reasonably be linked to a 282 
particular species (MRSA and FQR) or where we felt that their presence might impact 283 
treatment, regardless of the species of origin (ESBLS, plasmidic AmpCs and carbapenemases) 284 
(Table 1). A relatively large number of discrepancies in resistance detection were still noted. For 285 
example the Unyvero P50 detected 2 putative MRSA isolates, and a CTX-M producer in 286 
specimens reported to only contain normal respiratory flora. Comprehensive culture confirmed 287 
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a CTX-M producing K. pneumoniae was present in the latter, but unfortunately the presumptive 288 
MRSA specimens were not available for further study. It should be noted that the mecA assay of 289 
Unyvero P50 is not species specific and it is possible that the mecA genes in question originated 290 
from S. epidermidis rather than S. aureus [20].  During analysis, we only considered specimens 291 
where Unyvero P50 reported both S. aureus and mecA as potentially containing MRSA. 292 
Conversely, other discrepancies were potentially confusing. The majority of these related to the 293 
detection of chromosomal beta-lactamases. We suspect detection of chromosomal variants of 294 
AmpC enzymes (DHA in M. morganii and EBC (aka ACT/MIR) in Enterobacter spp [15]) in several 295 
cases; this is because there was no evidence for plasmidic AmpC enzymes in these specimens 296 
although the natural host species of these enzyme types were detected. Indeed, it can be 297 
difficult to develop PCR assays able to reliably distinguish certain plasmidic and chromosomal 298 
AmpC variants in their species of origin [21]. Five OXA-51 producing A. baumaniii were also 299 
detected; the OXA-51 enzyme is however intrinsic to A. baumannii and does not confer 300 
carbapenem resistance without an additional promoter provided by the insertion sequence 301 
ISAba1 [22]. Conversely, several A. baumannii isolated by routine microbiology carried blaOXA-23 302 
which is not a target of Unyvero P50.  303 
In our opinion, the composition of the resistance panel should be substantially redesigned to 304 
account for the common microflora of the respiratory tract and global distribution of beta-305 
lactamases. Several resistance genes, such as blaTEM, sul1 and ermB, are common among both 306 
pathogenic and commensal species found in the respiratory tract, and are therefore unusable 307 
unless their species of origin within the specimen is known. On the other hand, other resistance 308 
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genes causing concern globally, such as those encoding OXA-48, NDM and VIM type 309 
carbapenemases [23] are not included. 310 
Although the organism panel from the test is rather comprehensive, it could be further 311 
improved. Mycoplasma pneumoniae is not included as a target, and the test cannot 312 
differentiate between S. pneumoniae and other members of S. mitis group not relevant for 313 
respiratory tract infections [24] and should be replaced with an assay capable of detecting S. 314 
pneumoniae only. In addition, the complete lack of detection of viruses is a concern as viruses 315 
can account for a substantial amount of respiratory infections, especially during winter months. 316 
The manufacturer has recently released a new cartridge, the P55, addressing some of these 317 
issues. 318 
In summary, we find the sensitivity of detection of this test to be good, and therefore the 319 
treating clinician can be reasonably certain that if one of the targets of the test is absent, it is 320 
unlikely to be present, at least in significant numbers. Deciding which of the multiple organisms 321 
often detected in one specimen should be treated is another matter. As the specimens in this 322 
study all came from patients with known severe infections (42% were intensive care patients) it 323 
may be argued that many of the “additional” organisms detected by the test would have 324 
warranted treatment which could have improved outcomes for these patients, particular as the 325 
test is considerably faster than routine culture [19]. On the other hand, too many reported 326 
pathogens may unnecessarily confuse the physician’s choice of antimicrobial therapy, and may 327 
inadvertently lead to over-prescription of antimicrobials which would be detrimental to current 328 
efforts to improve antimicrobial stewardship worldwide [25]. Clinical studies evaluating the 329 
 
18 
 
potential effect on patient outcomes from use of technology such as the Curetis Unyvero P50 330 
are urgently required to establish the role this technology may play in the future microbiology 331 
laboratory.  332 
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TABLES 425 
Gram-positive 
Bacteria 
Gram-Negative Bacteria Fungus Resistance genes 
Staphylococcus aureus  
 
Streptococcus mitis 
group 
Acinetobacter baumanii, 
Escherischia coli, 
Haemophilus influenzae, 
Klebsiella oxytoca,  
Klebsiella pneumoniae,  
Moraxella catarrhalis,  
Morganella morganii,  
Pseudomonas aeruginosa,  
Serratia marcescens,  
Stenotrophomonas 
maltophilia,   
Chlamydophila pneumoniae,  
Legionella pneumophila,  
Enterobacter spp, 
Proteus spp 
Pneumocystis 
jirovecii 
blaCTX-M, blaDHA, blaEBC,  
ermA, ermB, ermC 
GyrA83, GyrA87, ParC 
blaKPC, blaoxa-51 
blaTEM, blaSHV,  
mefA, msrA, 
mecA,  
sul1 
int1 
Table 1. Pathogens and resistance markers detected by Unyvero P50. Resistance markers 426 
considered during our analyses are in bold.  427 
  428 
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Target Organism Routine 
laboratory 
UnyVero 
P50 
True Positive 
 (Routine and 
Unyvero P50) 
False Positive 
(Unyvero P50 
only) 
False Negative  
(Routine only) 
A. baumannii 3 10 3 7 0 
Enterobacter spp 3 9 3 6 0 
E. coli 5 8 5 3 0 
H. influenzae 3 7 1 6 2 
K. pneumoniae 3 11 3 8 0 
M. catarrhalis 3 6 3 3 0 
M. morganii 0 1 0 1 0 
Proteus spp 1 5 1 4 0 
P. aeruginosa 13 19 13 6 0 
S. marcescens 6 9 6 3 0 
S. aureus 5 11 5 6 0 
S. maltophilia 6 27 6 21 0 
S. mitis group* 0 13 0 13 0 
L. pneumophila 0 0 0 0 0 
C. pneumoniae 0 0 0 0 0 
P. jirovecii 0 0 0 0 0 
K. oxytoca 0 0 0 0 0 
E. faecalis 1 N/A 0 0 1 
C. koseri 1 N/A 0 0 1 
Negative 
specimens  
42 16 N/A N/A N/A 
Table 2. Frequency of organisms detected by routine microbiology and Unyvero P50 (n= 90 429 
specimens). Negative specimens include those classified by routine microbiology as NRF, NSG, 430 
MGODS or no growth. 431 
*S. mitis group is not considered significant by the routine microbiology laboratories, only 432 
confirmed detections as S. pneumoniae are reported. There were no reports of S. pneumoniae 433 
from these specimens. 434 
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 ESBL 
producer 
MRSA Fluoroquinolone 
resistance 
Carbapenemase 
producer 
AmpC producer 
 
Routine 
Microbiology + 
Checkpoints/PCR 
 
not detected 
 
n=1 
 
n=3  
 
1x P. aeruginosa 
(GyrA 83),  
2x  E. coli (GyrA 
83; GyrA 83 + 
GyrA 87) 
 
n=4 
 
3  A. baumannii      
(blaOXA-23) 
1  P. aeruginosa  
(no enzyme found) 
 
n=5 
 
3x S. marcescens  
2x E. aerogenes 
 
Presumed 
chromosomal AmpC 
upregulation 
 
 
Unyvero P50 
 
n=1 
blaCTX-M 
 
n=3* 
 
n=3  
 
1x  P. aeruginosa 
(GyrA83, ParC) 
2x  E. coli 
(GyrA83, GyrA83 
+ GyrA87) 
 
n=5 blaOXA-51 
 
2x  A. baumannii 
 
1x A. baumanii  
    + S. maltophilia 
 
2x  A. baumannii  
     + S. maltophilia  
     + S.aureus  
 
 
n=5 
 
2 x blaDHA 
 
1x M. morganii  
    + S. marcescens 
 
1x P. aeruginosa 
   + S. maltophilia 
 
            3 x blaEBC 
 
2x Enterobacter spp. 
 
1x Enterobacter spp                  
    + M. catarrhalis 
 
Concordance No 1/3 2/3 No No 
 436 
Table 3. Number of potentially significant resistance mechanisms detected by routine 437 
microbiology versus Unyvero P50 438 
*We assumed presence of MRSA when both S. aureus and mecA were detected in the specimen 439 
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FIGURES 441 
 442 
Figure 1. Distribution of the number of micro-organisms detected per specimen 443 
 444 
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445 
Figure 2 Summary of results  446 
